Project leader: Najla FOURATI
For diagnosis and therapy - (14/10/2022)
Prostate cancer (PCa) is the most common cancer in France. Prostate-specific antigen (PSA) is the reference biomarker for its detection and diagnosis. However, the presence of high levels of PSA can also reflect other non-cancerous pathologies of the prostate, such as benign prostatic hyperplasia or prostatitis. To overcome the limitations of PSA, the approach of this project is to develop a lab-on-a-chip that allows reliable measurement of three CaP biomarkers, two of which are urinary. It will provide clinicians a non-invasive diagnostic tool for prostate cancer thanks to rapid, in situ biomarker quantification.
Contact : Najla FOURATI (UMR 8029 SATIE – Pôle SIAME)
